Home > Haematology > Alteplase benefits similar when given 6 to 9 vs. 4.5 to 6 hours from stroke onset

Alteplase benefits similar when given 6 to 9 vs. 4.5 to 6 hours from stroke onset

Journal
JAMA Neurology
Reuters Health - 02/11/2020 - Alteplase appears no less effective when given between six and nine hours from stroke onset, or from midpoint of sleep, versus between 4.5 and six hours in patients with perfusion mismatch, according to a meta-analysis of data from the EXTEND and EPITHET trials. "These data provide support for implementation of intravenous thrombolysis in patients who fall within the full time window up to 9 hours since last known well or midpoint of sleep and who were eligible in the EXTEND trial," Dr. Bruce Campbell of Royal Melbourne Hospital and the University of Melbourne, in Parkville, Australia, and colleagues write in JAMA Neurology. "Further trials will test whether intravenous thrombolysis can benefit patients with perfusion mismatch up to 24 hours after the time they were last known to be well," they add. In an earlier meta-analysis of individual patient data from the EXTEND, ECASS4-EXTEND and EPITHET randomized trials, the researchers...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on